Brief: Sygnis Raises 2018 FY Revenue Guidance At Between EUR 13-14 Mln
Brief: Sygnis Q1 EBITDA Swings To Positive EUR 50,000
Brief: Sygnis Completes Acquisition Of TGR Biosciences
Brief: Sygnis AG Obtains Finance To Close Acquisition Of Australian TGR Biosciences
Brief: Sygnis FY Net Loss At EUR 3.3 Million
Brief: Sygnis Raises About EUR 4.2 Mln In Private Placement
Brief: Sygnis Ag To Raise Capital To Acquire TGR Biosciences
Brief: Sygnis To Raise Capital To Buy TGR Biosciences
Brief: Sygnis To Restructure Sales And Marketing Team
Brief: Sygnis Integrates Acquired Companies' Products And Services Under Expedeon Brand Name
Brief: Sygnis Extends OEM Agreement With Global Research Tools Provider
Brief: Sygnis Signs Supply Agreement With US Biological
Brief: Sygnis reports net loss for 9 months at EUR 3.1 mln
Brief: SYGNIS partners with Abingdon Health
Brief: Sygnis files a patent application
Brief: Sygnis: relocation of Innova Biosciences unit to allow for expansion
Brief: Sygnis H1 net loss at EUR 2.0 mln
Brief: Sygnis says AGM resolved to create new authorized capital in amount of Euro 22.4 mln
Brief: Sygnis resolves share price of 1.38 euros for capital increase